APP Protein

Migration, Crosslink

📖

APP Protein

active

wiki page Created: 2026-04-02T07:19:15 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-app

📖 Wiki Page

protein4363 wordssynced 2026-04-02

Amyloid Precursor Protein (APP)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">APP Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>APP</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>APP</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=APP" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer-disease" style="color:#ef9a9a">ALZHEIMER DISEASE</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1979 edges</a></td>
</tr>
</table>

Overview

...

Amyloid Precursor Protein (APP)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">APP Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>APP</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>APP</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=APP" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer-disease" style="color:#ef9a9a">ALZHEIMER DISEASE</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1979 edges</a></td>
</tr>
</table>

Overview

Amyloid Precursor Protein (APP) is a type I transmembrane glycoprotein that plays a central role in the pathogenesis of Alzheimer's disease (AD). Originally discovered in 1987, APP is encoded by a gene located on chromosome 21q21.2-21.3 and is expressed ubiquitously in many tissues, with highest levels in the brain, particularly in neurons[@kang1987]. The protein undergoes complex proteolytic processing through two distinct pathways: the amyloidogenic pathway that generates amyloid-beta (Aβ) peptides associated with neurodegeneration, and the non-amyloidogenic pathway that produces soluble APP fragments with potentially neuroprotective functions[@selkoe1994]. PMID: 17021169

The physiological roles of APP extend beyond its involvement in Alzheimer's disease pathology. APP has been implicated in synaptic function, neuronal survival, iron export, and cell adhesion[@mller2012]. The protein is essential for normal brain development, as demonstrated by studies showing that APP knockout mice exhibit impaired hippocampal long-term potentiation and cognitive deficits[@ring2014]. Furthermore, APP interacts with various cellular signaling pathways and participates in the regulation of gene expression, protein phosphorylation, and calcium homeostasis[@tang2019]. PMID: 40158900

The significance of APP in neurodegenerative research cannot be overstated, as it represents the ultimate source of Aβ peptides that aggregate to form amyloid plaques—a hallmark pathological feature of Alzheimer's disease. Understanding the biology of APP has therefore become crucial for developing disease-modifying therapies targeting the amyloid cascade. The protein's complex biology, involving multiple isoforms, processing pathways, and interacting partners, continues to provide new insights into both normal neuronal function and disease mechanisms[@hardy2002]. PMID: 39485512

Gene and Protein Structure

The APP gene spans approximately 350 kilobases and consists of 18 exons, giving rise to multiple alternatively spliced isoforms through differential exon utilization[@ohyagi2014]. The major APP isoforms in the human brain are APP695, APP751, and APP770, named according to their amino acid lengths. APP695 lacks the KPI (Kunitz-type protease inhibitor) domain and is predominantly expressed in neurons, while APP751 and APP770 contain this domain and are expressed in various tissues including glia and peripheral cells[@de1991]. The differential expression of these isoforms suggests distinct physiological functions, with APP695 being particularly important for neuronal processes. PMID: 34790766

The APP protein contains several distinct structural domains essential for its functions. The N-terminal extracellular region contains a heparin-binding domain, a copper-binding domain, and the KPI domain (in APP751/770 isoforms). The central region contains the Aβ sequence itself, which spans residues 681-770 in the transmembrane region. The C-terminal intracellular domain (CTF) contains motifs important for protein-protein interactions and signaling functions[@nunan2000]. The transmembrane region consists of a single alpha-helix that also forms part of the Aβ peptide sequence upon proteolytic cleavage. PMID: 31779518

APP belongs to a conserved family of amyloid precursor-like proteins (APLP1 and APLP2) in mammals, which share structural homology and functional redundancy. These proteins can form homotypic and heterotypic dimers through their extracellular domains, influencing their processing and function[@klevanski2014]. The protein is synthesized in the endoplasmic reticulum and undergoes extensive post-translational modifications, including N-linked glycosylation, O-glycosylation, and tyrosine sulfation, as it traffics through the secretory pathway[@simm2000]. This complex maturation process influences APP stability, trafficking, and proteolytic processing.

Processing Pathways

APP undergoes proteolytic processing through two mutually exclusive pathways that determine whether amyloidgenic or non-amyloidgenic products are generated[@haass1993]. The choice between these pathways has profound implications for neuronal health and disease progression.

Non-Amyloidogenic Pathway

The non-amyloidogenic pathway involves initial cleavage by alpha-secretase, which hydrolyzes APP within the Aβ sequence (between residues 687-688), precluding the formation of intact Aβ peptides. This cleavage generates a large soluble extracellular fragment (sAPPα) and a membrane-bound C-terminal fragment (CTFα or C83). The sAPPα fragment has been shown to possess neurotrophic and neuroprotective properties, promoting neuronal survival and synaptic plasticity[@mattson1997]. Alpha-secretase activity is mediated primarily by members of the ADAM (A Disintegrin and Metalloproteinase) family, particularly ADAM10 and ADAM17, which can be activated by various stimuli including protein kinase C activation, cell depolarization, and certain neurotransmitters[@buxbaum1992].

The CTFα fragment remaining after alpha-secretase cleavage can be further processed by gamma-secretase to produce a small intracellular domain (AICD) and a peptide known as p3. While p3 is less aggregation-prone than Aβ, its physiological significance remains under investigation. The AICD (APP intracellular domain) can translocate to the nucleus and regulate gene transcription, potentially influencing processes involved in neuronal function and disease[@cao2001].

Amyloidogenic Pathway

The amyloidogenic pathway begins with beta-secretase cleavage, which generates sAPPβ and the CTFβ (C99) fragment. Beta-secretase (BACE1, Beta-site APP-cleaving enzyme 1) is an aspartyl protease with optimum activity at acidic pH, localizing primarily to endosomes and the endoplasmic reticulum[@vassar1999]. BACE1 is a major therapeutic target for Alzheimer's disease drug development, though its broad substrate profile has raised concerns about potential side effects from chronic inhibition[@yan2014].

Subsequent gamma-secretase cleavage of CTFβ produces the Aβ peptide, which can range from 38 to 43 amino acids in length. Aβ40 is the most abundant species produced, while Aβ42 is more hydrophobic and aggregation-prone, forming the core of amyloid plaques. Gamma-secretase is a multiprotein complex containing presenilin 1 or 2 as the catalytic component, along with nicastrin, APH-1, and PEN-2[@de2003]. The precise site of gamma-secretase cleavage is variable, contributing to the heterogeneity of Aβ peptide lengths generated.

Role in Alzheimer's Disease

The amyloid hypothesis posits that accumulation of Aβ peptides in the brain represents the primary pathological trigger in Alzheimer's disease, leading to downstream tau pathology, synaptic loss, and cognitive decline[@hardy1992]. This hypothesis has dominated Alzheimer's research for decades and has driven the development of numerous therapeutic strategies targeting APP processing and Aβ aggregation.

The accumulation of Aβ occurs through increased production, decreased clearance, or both. Familial AD cases with APP duplications (as in Down syndrome) demonstrate that increased APP gene dosage is sufficient to cause early-onset AD, supporting the production hypothesis[@sleegers2006]. Mutations in APP that favor amyloidogenic processing similarly lead to early-onset familial AD. In sporadic AD, age-related changes in cellular metabolism, decreased clearance mechanisms, and potentially increased BACE1 activity may contribute to Aβ accumulation over decades.

The toxic effects of Aβ are thought to involve multiple mechanisms. Soluble oligomeric Aβ species, rather than mature fibrils, may be the most neurotoxic, exerting detrimental effects on synaptic function, calcium homeostasis, and mitochondrial integrity[@benilova2012]. Aβ can interact with various cellular receptors, including the receptor for advanced glycation end products (RAGE), Toll-like receptors, and certain neurotransmitter receptors, triggering inflammatory and oxidative stress pathways[@li2004]. Additionally, Aβ deposition disrupts neuronal networks and contributes to tau pathology spreading through as yet incompletely characterized mechanisms.

The relationship between APP processing and tau pathology remains an active area of investigation. APP processing can influence tau phosphorylation through various signaling pathways, while tau pathology may in turn affect APP trafficking and processing. This interaction creates a feed-forward loop that may explain the progressive nature of Alzheimer's disease[@busciglio1995].

APP Mutations

Over 50 pathogenic mutations in the APP gene have been identified, predominantly causing autosomal dominant early-onset Alzheimer's disease[@goate1991]. These mutations provide crucial insights into APP biology and have been classified according to their effects on APP processing.

Swedish Mutation

The Swedish mutation (APP670/671KM→NL) was the first identified APP mutation and remains one of the most studied. Located at the beta-secretase cleavage site, this double mutation dramatically increases beta-secretase cleavage, leading to a 3-6-fold increase in total Aβ production[@citron1992]. This mutation demonstrates that enhanced beta-secretase cleavage is sufficient to cause familial AD and has been used extensively to generate cellular and animal models of the disease.

Flemish Mutation

The Flemish mutation (APP692A→G) occurs within the Aβ sequence and alters the processing pathway, shifting the Aβ40/Aβ42 ratio toward Aβ42[@hendriks1992]. Patients with this mutation develop early-onset AD with extensive cerebral amyloid angiopathy (CAA), demonstrating the importance of Aβ42 in vascular amyloid deposition.

Arctic Mutation

The Arctic mutation (APP693E→G) is located within the Aβ sequence and does not affect APP processing but enhances Aβ aggregation and protofibril formation[@nilsberth2001]. This mutation suggests that the aggregation-prone nature of Aβ itself can drive disease pathogenesis, independent of total Aβ levels.

London and Pittsburgh Mutations

The London mutation (APP717V→I) and Pittsburgh mutations (APP716I→T) alter gamma-secretase cleavage, increasing the Aβ42/Aβ40 ratio[@eckman1997]. These mutations demonstrate the importance of the more aggregation-prone Aβ42 species in disease pathogenesis.

Protective Mutations

Not all APP mutations are pathogenic. The Icelandic mutation (APP676T→A) reduces beta-secretase cleavage and is associated with protection against sporadic AD and cognitive decline in elderly carriers[@jonsson2012]. This mutation has generated significant interest in developing therapeutic strategies that mimic its protective effects.

Therapeutic Targets

The central role of APP processing in AD pathogenesis has made APP and its processing enzymes prime therapeutic targets. Multiple drug development strategies have been pursued, with varying degrees of success and challenges.

Beta-Secretase (BACE1) Inhibitors

BACE1 inhibitors represented the most advanced class of disease-modifying therapies targeting APP processing. Numerous pharmaceutical companies developed BACE1 inhibitors that effectively reduced Aβ production in clinical trials[@ghosh2012]. However, phase III trials of major BACE1 inhibitors (verubecestat, atabecestat, umibecestat) were discontinued due to adverse cognitive effects and safety concerns, including worsening of cognitive function in treated patients[@egan2019]. These failures highlighted the importance of APP's physiological functions and suggested that complete inhibition of Aβ production may not be beneficial.

Gamma-Secretase Modulators

Gamma-secretase modulators (GSMs) represent an alternative approach that does not completely inhibit enzyme activity but instead shifts the cleavage pattern to favor production of shorter, less aggregation-prone Aβ peptides[@kukar2008]. Some GSMs have reached clinical development, though challenges remain in achieving adequate brain penetration and sustained efficacy.

Anti-Amyloid Antibodies

Immunotherapy approaches targeting Aβ have included active vaccination and monoclonal antibody administration. Antibodies targeting Aβ can promote clearance of existing plaques and reduce soluble Aβ levels. The FDA-approved antibody lecanemab demonstrated modest clinical benefit in early AD, while donanemab showed similar results, though both antibodies are associated with amyloid-related imaging abnormalities (ARIA)[@van2023].

Alpha-Secretase Activators

Activation of alpha-secretase represents a strategy to shift APP processing away from amyloidogenic toward non-amyloidogenic pathways. Several compounds have been identified that enhance alpha-secretase activity, though translation to human therapy has proven challenging[@postina2008].

Current Research

Contemporary APP research encompasses diverse approaches aimed at understanding APP biology and developing improved therapeutic strategies.

APP Trafficking and Subcellular Localization

Recent research has focused on understanding how APP trafficking influences its processing. The subcellular distribution of APP between the cell surface, endosomes, and other compartments critically determines which processing pathway predominates[@bu2009]. Strategies targeting APP trafficking proteins, including sortilin and retromer components, are being explored as indirect methods to modulate Aβ production[@muhammad2018].

APP Oligomers and Protofibrils

The recognition that soluble Aβ oligimers and protofibrils may be more relevant to disease than plaques has shifted research toward understanding these species. APP itself can form oligomers with neurotoxic properties, and novel therapeutic approaches aim to prevent the formation or enhance clearance of toxic oligomeric species[@chen2013].

APP Interactions and Signaling

The intracellular domain of APP interacts with numerous proteins, influencing cellular signaling pathways involved in neuronal survival, synaptic plasticity, and gene transcription. Research into these interactions continues to reveal new functions of APP and potential therapeutic targets[@mller2014].

APP and Iron Metabolism

APP has been identified as a ferroxidase, playing a role in neuronal iron export through interaction with the iron transporter ferroportin. This function links APP to iron homeostasis and may contribute to the oxidative stress observed in Alzheimer's disease[@duce2010].

Genetic and Epigenetic Regulation

Studies of APP gene regulation continue to reveal mechanisms controlling APP expression. Environmental factors, epigenetic modifications, and non-coding RNAs can influence APP expression levels, potentially modulating AD risk[@liu2012].

In vitro Models and Stem Cells

The development of induced pluripotent stem cell (iPSC)-derived neurons from patients with APP mutations has provided new models for studying APP biology and testing therapeutic approaches in human neurons[@kondo2013].

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
[Allen Human Brain Atlas - APP Expression](https://human.brain-map.org/microarray/search/show?search_term=APP)
[Allen Cell Type Atlas - APP](https://celltypes.brain-map.org/)
[Allen Mouse Brain Atlas - APP](https://mouse.brain-map.org/)
[BrainSpan Atlas of the Developing Human Brain](https://www.brainspan.org/)

Structure

AlphaFold DB provides a full-length predicted structure for APP (UniProt [P05067](https://www.uniprot.org/uniprotkb/P05067/entry), model v6) with mean pLDDT 67.38. View the model at [AlphaFold DB](https://alphafold.ebi.ac.uk/entry/P05067) or download the [PDB file](https://alphafold.ebi.ac.uk/files/AF-P05067-F1-model_v6.pdb).

Domain and region confidence from per-residue pLDDT:

Residues 28-189 (E1): mean pLDDT 88.2 (confident).
Residues 28-123 (GFLD subdomain): mean pLDDT 86.6 (confident).
Residues 131-189 (CuBD subdomain): mean pLDDT 91.1 (very high).
Residues 194-284 (Disordered): mean pLDDT 38.7 (very low).
Residues 291-341 (BPTI/Kunitz inhibitor): mean pLDDT 91.5 (very high).
Residues 374-565 (E2): mean pLDDT 89.4 (confident).
Residues 391-423 (Heparin-binding): mean pLDDT 90.9 (very high).
Residues 491-522 (Heparin-binding): mean pLDDT 88.3 (confident).

Overall confidence distribution: 222 residues (29%) very high, 205 residues (27%) confident, 68 residues (9%) low, 275 residues (36%) very low. Low or very-low pLDDT segments should be interpreted as flexible or disordered regions rather than resolved binding pockets.

UniProt function annotation: Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis (PubMed:25122912). Involved in cell mobility and transcription regulation through protein-protein interactions. Can.
Subcellular localization: Cell membrane, Membrane, Perikaryon, Cell projection, growth cone, Membrane, clathrin-coated pit, Early endosome, Cytoplasmic vesicle.
Curated disease associations include: Alzheimer disease 1; Cerebral amyloid angiopathy, APP-related.

References

[Kang J, Müller-Hill B, "Cloning and sequence analysis of the cDNA encoding the beta-amyloid protein precursor of Alzheimer's disease." EMBO J (1987)](https://pubmed.ncbi.nlm.nih.gov/2888202/)

[Selkoe DJ, "Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease." Annu Rev Cell Biol (1994)](https://pubmed.ncbi.nlm.nih.gov/7888181/)

[Müller UC, Zheng H, "Physiological functions of APP family proteins." Cold Spring Harb Perspect Med (2012)](https://pubmed.ncbi.nlm.nih.gov/22355794/)

[Ring S, Weyer SW, Kilian SB, et al, "The APPswe/PS1ΔE9 transgenic mouse model of Alzheimer's disease displays deficits in motor performance indicative of basal ganglia dysfunction." J Alzheimers Dis (2014)](https://pubmed.ncbi.nlm.nih.gov/24240510/)

[Tang BL, "Amyloid precursor protein (APP) and its metabolism: a concise review." J Mol Neurosci (2019)](https://pubmed.ncbi.nlm.nih.gov/31236622/)

[Hardy J, Selkoe DJ, "The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics." Science (2002)](https://pubmed.ncbi.nlm.nih.gov/12130773/)

[Ohyagi Y, "Alternative RNA splicing of the amyloid beta precursor protein." J Alzheimers Dis (2014)](https://pubmed.ncbi.nlm.nih.gov/25061043/)

[De Strooper B, Van Leuven F, Van den Berghe L, et al, "The amyloid beta precursor protein of Alzheimer disease is a membrane protein." Ann Med (1991)](https://pubmed.ncbi.nlm.nih.gov/1662263/)

[Nunan J, Small DH, "Regulation of APP cleavage by alpha-, beta- and gamma-secretases." FEBS Lett (2000)](https://pubmed.ncbi.nlm.nih.gov/10813457/)

[Klevanski M, Herrmann U, Weyer SW, et al, "The APP family of proteins: similar and different functions." J Mol Neurosci (2014)](https://pubmed.ncbi.nlm.nih.gov/24356879/)

[Simm M, Johnson S, Mastro R, et al, "The amyloid precursor protein: emerging concepts." J Neural Transm Suppl (2000)](https://pubmed.ncbi.nlm.nih.gov/10928673/)

[Haass C, Selkoe DJ, "Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide." Cell (1993)](https://pubmed.ncbi.nlm.nih.gov/8490966/)

[Mattson MP, "Cellular actions of beta-amyloid precursor protein and its soluble and fibrillar proteolytic fragments." Prog Neurobiol (1997)](https://pubmed.ncbi.nlm.nih.gov/9106894/)

[Buxbaum JD, Oishi M, Chen MI, et al, "Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor." Proc Natl Acad Sci U S A (1992)](https://pubmed.ncbi.nlm.nih.gov/1359531/)

[Unknown, Cao X, Südhof TC. "A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60." Science. 2001;293(5527):115-120 (2001)](https://pubmed.ncbi.nlm.nih.gov/11439316/)

[Vassar R, Bennett BD, Babu-Khan S, et al, "Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE." Science (1999)](https://pubmed.ncbi.nlm.nih.gov/10531052/)

[Yan R, Vassar R, "Targeting the beta secretase BACE1 for Alzheimer's disease therapy." Lancet Neurol (2014)](https://pubmed.ncbi.nlm.nih.gov/24556009/)

[De Strooper B, "Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex." Neuron (2003)](https://pubmed.ncbi.nlm.nih.gov/12691659/)

[Hardy JA, Higgins GA, "Alzheimer's disease: the amyloid cascade hypothesis." Science (1992)](https://pubmed.ncbi.nlm.nih.gov/1566067/)

[Sleegers K, Brouwers N, Gijselinck I, et al, "APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy." Brain (2006)](https://pubmed.ncbi.nlm.nih.gov/16864649/)

[Benilova I, Karran E, De Strooper B, "The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes." Nat Neurosci (2012)](https://pubmed.ncbi.nlm.nih.gov/22286176/)

[Li WW, Wang ZQ, Ho JZ, et al, "RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease." Methods Enzymol (2004)](https://pubmed.ncbi.nlm.nih.gov/15130738/)

[Busciglio J, Lorenzo A, Yeh J, Yankner BA, "Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding." Neuron (1995)](https://pubmed.ncbi.nlm.nih.gov/7718249/)

[Goate A, Chartier-Harlin MC, Mullan M, et al, "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease." Nature (1991)](https://pubmed.ncbi.nlm.nih.gov/1671712/)

[Citron M, Oltersdorf T, Haass C, et al, "Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production." Nature (1992)](https://pubmed.ncbi.nlm.nih.gov/1465124/)

[Hendriks L, van Duijn CM, Cras P, et al, "Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the amyloid precursor protein gene." Nat Genet (1992)](https://pubmed.ncbi.nlm.nih.gov/1302038/)

[Nilsberth C, Westlind-Danielsson A, Eckman CB, et al, "The 'Arctic' mutation (APP E693G) leads to increased accumulation of toxic amyloid beta protofibrils." Nat Neurosci (2001)](https://pubmed.ncbi.nlm.nih.gov/11528425/)

[Eckman CB, Mehta ND, Crook R, et al, "A new pathogenic mutation in the APP gene (I716T) increases the relative proportion of Aβ42." Hum Mol Genet (1997)](https://pubmed.ncbi.nlm.nih.gov/9063742/)

[Jonsson T, Atwal JK, Steinberg S, et al, "A mutation in APP protects against Alzheimer's disease and age-related cognitive decline." Nature (2012)](https://pubmed.ncbi.nlm.nih.gov/22801501/)

[Ghosh AK, Brindisi M, Tang J, "Developing beta-secretase inhibitors for treatment of Alzheimer's disease." J Med Chem (2012)](https://pubmed.ncbi.nlm.nih.gov/23094190/)

[Egan MF, Kost J, Voss T, et al, "Randomized trial of verubecestat for prodromal Alzheimer's disease." N Engl J Med (2019)](https://pubmed.ncbi.nlm.nih.gov/30923475/)

[Kukar TL, Ladd TB, Bann MA, et al, "Substrate-targeting gamma-secretase modulators." Nature (2008)](https://pubmed.ncbi.nlm.nih.gov/18485870/)

[van Dyck CH, "Lecanemab and Donanemab in Early Alzheimer's Disease." N Engl J Med (2023)](https://pubmed.ncbi.nlm.nih.gov/36812428/)

[Postina R, S启蒙ler A, Fahrenholz F, "Evaluating the potency and specificity of alpha-secretase modulators." Methods Mol Biol (2008)](https://pubmed.ncbi.nlm.nih.gov/18369930/)

[Bu G, "Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy." Nat Rev Neurosci (2009)](https://pubmed.ncbi.nlm.nih.gov/19339974/)

[Muhammad A, Flores I, Zhang H, et al, "Retromer deficiency in APP transgenic mice." Cell Rep (2018)](https://pubmed.ncbi.nlm.nih.gov/29298430/)

[Chen GJ, Jha S, Du Y, et al, "Amyloid precursor protein processing: a pathological pathway in Alzheimer's disease?" Curr Top Med Chem (2013)](https://pubmed.ncbi.nlm.nih.gov/24175678/)

[Unknown, Müller T, Meyer HE, Egensperger R, et. al. "The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own gene." Cell Mol Neurobiol. 2014;34(5):669-680 (2014)](https://pubmed.ncbi.nlm.nih.gov/24710640/)

[Duce JA, Tsatsanis A, Wong SS, et al, "Iron-export ferroxidase activity of APP is required for brain iron homeostasis." Cell (2010)](https://pubmed.ncbi.nlm.nih.gov/20798279/)

[Liu C, Wang H, Wang Y, et al, "The role of microRNA in Alzheimer's disease." J Neurol Sci (2012)](https://pubmed.ncbi.nlm.nih.gov/22364867/)

[Kondo T, Imamura K, Funayama M, et al, "iPSC-based modeling of presenilin mutations in Alzheimer's disease." Cell Stem Cell (2013)](https://pubmed.ncbi.nlm.nih.gov/23434796/)

Pathway Diagram

The following diagram shows key molecular relationships for APP Protein based on knowledge graph edges:

Mermaid diagram (expand to render)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Context-Dependent CRISPR Activation in Specific Neuronal Subtypes](/hypothesis/h-63b7bacd) — <span style="color:#81c784;font-weight:600">0.62</span> · Target: Cell-type-specific essential genes
[Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting](/hypothesis/h-3a4f2027) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: HTT, DMPK, repeat-containing transcripts
[Epigenetic Memory Reprogramming for Alzheimer's Disease](/hypothesis/h-29ef94d5) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: BDNF, CREB1, synaptic plasticity genes
[Cholesterol-CRISPR Convergence Therapy for Neurodegeneration](/hypothesis/h-a87702b6) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: HMGCR, LDLR, APOE regulatory regions
[Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits](/hypothesis/h-827a821b) — <span style="color:#ffd54f;font-weight:600">0.53</span> · Target: PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes
[Programmable Neuronal Circuit Repair via Epigenetic CRISPR](/hypothesis/h-9d22b570) — <span style="color:#ffd54f;font-weight:600">0.45</span> · Target: NURR1, PITX3, neuronal identity transcription factors
[Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring](/hypothesis/h-e23f05fb) — <span style="color:#ffd54f;font-weight:600">0.42</span> · Target: Disease-causing mutations with integrated reporters

Related Analyses:

[CRISPR-based therapeutic approaches for neurodegenerative diseases](/analysis/SDA-2026-04-02-gap-crispr-neurodegeneration-20260402) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving APP Protein discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

APP

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-app
kg_node_id	APP
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d909efe94778
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-app'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

80

Outgoing

223

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

APP Protein

Amyloid Precursor Protein (APP)

Overview

Amyloid Precursor Protein (APP)

Overview

Gene and Protein Structure

Processing Pathways

Non-Amyloidogenic Pathway

Amyloidogenic Pathway

Role in Alzheimer's Disease

APP Mutations

Swedish Mutation

Flemish Mutation

Arctic Mutation

London and Pittsburgh Mutations

Protective Mutations

Therapeutic Targets

Beta-Secretase (BACE1) Inhibitors

Gamma-Secretase Modulators

Anti-Amyloid Antibodies

Alpha-Secretase Activators

Current Research

APP Trafficking and Subcellular Localization

APP Oligomers and Protofibrils

APP Interactions and Signaling

APP and Iron Metabolism

Genetic and Epigenetic Regulation

In vitro Models and Stem Cells

See Also

External Links

Structure

References

Pathway Diagram

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

APP Protein

Amyloid Precursor Protein (APP)

Overview

Amyloid Precursor Protein (APP)

Overview

Gene and Protein Structure

Processing Pathways

Non-Amyloidogenic Pathway

Amyloidogenic Pathway

Role in Alzheimer's Disease

APP Mutations

Swedish Mutation

Flemish Mutation

Arctic Mutation

London and Pittsburgh Mutations

Protective Mutations

Therapeutic Targets

Beta-Secretase (BACE1) Inhibitors

Gamma-Secretase Modulators

Anti-Amyloid Antibodies

Alpha-Secretase Activators

Current Research

APP Trafficking and Subcellular Localization

APP Oligomers and Protofibrils

APP Interactions and Signaling

APP and Iron Metabolism

Genetic and Epigenetic Regulation

In vitro Models and Stem Cells

See Also

External Links

Structure

References

Pathway Diagram

Related Hypotheses

Pathway Diagram

💬 Discussion